Kelun pharmaceutical is expected to obtain 7 new drug production approvals this year

Wang Jingyi, chief scientist of Kelun pharmaceutical, said at the performance briefing on May 12 that the company is expected to obtain seven new drug production approvals this year It is worth noting that in the field of parenteral nutrition, Kelun pharmaceutical, based on the original fat emulsion injection, developed and applied for series parenteral nutrition infusion such as medium and long chain fat emulsion injection and long chain fat emulsion injection The first three cavity bag nutrition infusion also applied for CDE (National Drug Review Center) queuing for review last year As for the approval time of new drugs, Wang Jingyi said that the waiting time of CDE evaluation and sorting is difficult to predict finally Generally, the projects can only obtain the production approval documents within 3-5 years The company will make preparations before approval and strive to promote and accelerate the product listing as much as possible Since 2013, the R & D of new drugs in Kelun pharmaceutical industry has been promoted rapidly, and the applied drugs are mostly generic drugs in digestive tract, tumor and other fields The company's annual report indicates that 42 class a projects have been declared, including 20 production projects The annual R & D investment has exceeded 400 million yuan, up 99.74% year-on-year, accounting for 5.86% of the operating revenue